Views & Analysis | Perspectives on pharma industry issues

Oncology

Australia, CAR-T therapy, and solid tumours

Bev Menner, chief executive officer at Cell Therapies Pty Ltd, discusses CAR-T therapies for solid tumours and Australian and APAC R&D more generally.

Market Access

Two business hands outstretched, one weighing cash, the other drugs, for balance

What the revised 340B rebate pilot programme means for pharm...

While the scope of the revised pilot is limited, it may be a harbinger for a broader policy shift.

Digital

IQVIA Technologies sponsored podcast, with Updesh Dosanjh

AI-enabled pharmacovigilance, with Updesh Dosanjh

Updesh Dosanjh, IQVIA commercialisation lead for safety technology, discusses how and why the role of AI in pharmacovigilance is changing.

Digital

Two female silhouettes in a city office overlook the urban landscape below

How female leadership can benefit industry

Day One Strategy’s founding partners Abigail Stuart and Hannah Mann share the benefits female leadership can bring to industry.

Patients

Maintenance: The underexamined half of the GLP-1 story

GLP-1 treatments have historically had an exit problem, as appetite suppression stops when the medication stops.

Views & Analysis

Cost concerns with the new NHS pricing scheme

A new pricing scheme, which took effect this month, has raised the cap on NHS spending on branded drugs slightly.

Views & Analysis

Market access roundup: The US fights back against price hike...

Don’t expect the US government’s war on drug pricing to go away any time soon – for once president Trump and his rivals, the Democrat party, agree on something, and both have had some stron

Views & Analysis

An echo through brain cancer’s empty pipeline

Brain tumours kill more people aged under 40 than any other cancer, yet there have been no new treatments for more than a decade. What’s more, there are still none in the pipeline.

Sales & Marketing

Accelerating growth through strategic investment in healthca...

CEVA FORPATIENTS at Rockingham, UK will offer the healthcare supply chain a new, sustainably designed multi-user site.

Sales & Marketing

The patient communication crisis pharma can no longer ignore

Industry's significant investments in patient engagement are only effective if patients trust the communication enough to answer in the first place.

Digital

AI-enabled pharmacovigilance, with Updesh Dosanjh

Updesh Dosanjh, IQVIA commercialisation lead for safety technology, discusses how and why the role of AI in pharmacovigilance is changing.

Digital

How female leadership can benefit industry

Day One Strategy’s founding partners Abigail Stuart and Hannah Mann share the benefits female leadership can bring to industry.

Market Access

What the revised 340B rebate pilot programme means for pharm...

While the scope of the revised pilot is limited, it may be a harbinger for a broader policy shift.

Market Access

$100 notes in pill bottle on aquamarine background with spilled pills

How new PBM transparency rules will alter drug pricing

The complex drug pricing ecosystem means all stakeholders are scrambling to understand how the new regulations and PBMs’ adjustments will impact them.

Oncology

Australia, CAR-T therapy, and solid tumours

Bev Menner, chief executive officer at Cell Therapies Pty Ltd, discusses CAR-T therapies for solid tumours and Australian and APAC R&D more generally.

Oncology